arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TherapeuticsMD, Inc.

TXMD
$1.71 ▼ -0.11 (-6.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

TherapeuticsMD, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $19.8M
Dividend Yield —
Revenue Growth -8.7% ↘
Op. Margin -93.9% ↗
ROIC -2.4% ↘
FCF / Share None
Trailing P/E 171.0x
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$869.00K
↓ -8.7% —
Net Income Profit after all expenses
$95.00K
— 0.0% —
Operating Margin Operating profit as % of sales
-93.9%
↑ +6.0% 1th
FCF / Share Free cash flow per share
$-0.89
↑ +74.0% —
Long-Term Debt Long-term obligations
$93.60M
↑ +3.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
7
Returns
41
Financial Health ↓
6

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 16 years · 66 quarters